Study to evaluate methods that assess the effect of AZD4017 in adipose tissue
Study identifier:D2060M00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, single-blind, placebo-controlled, single-centre, Phase I study in abdominally obese healthy volunteers to evaluate methods to assess 11-βHSD1 activity in adipose tissue and related downstream biomarkers after single and repeated oral doses of AZD4017 for 10 days
Medical condition
obesity
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD4017, Placebo
Sex
Male
Actual Enrollment
15
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Mar 2010
Primary Completion Date: 01 May 2010
Study Completion Date: 01 May 2010
Study design
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Other
Verification:
Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD4017 oral suspension, 1200mg, once daily, for 10 days |
| Placebo Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Per-Anders Jansson
Avdelningen för molekylär och klinisk medicin Lundberglaboratoriet
